Mason Street Advisors’s Crescent Biopharma CBIO Stock Holding History

Mason Street Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,020	Closed	-$734K	–	1598
2014 Q4	$734K	Hold	1,020	–	–	0.01%	1276
2014 Q3	$708K	Hold	1,020	–	–	0.01%	1272
2014 Q2	$860K	Buy	1,020 +241	+31%	+$240K	0.01%	1221
2014 Q1	$1.27M	Buy	+779	New	+$943K	0.01%	1107

Other funds holding CBIO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WSA

Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return

SIM

Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Mason Street Advisors's CBIO Position: Q1 2015 in Review

Mason Street Advisors sold out of Crescent Biopharma (CBIO) in Q1 2015, closing a stake of 1,020 shares — an estimated $734K sold.

Mason Street Advisors first reported a position in CBIO in Q1 2014 and held it in 4 quarters. The position peaked at $1.27M in Q1 2014. 28 funds tracked by Wall St. Rank hold CBIO as of Q1 2015.

Mason Street Advisors reported no remaining Crescent Biopharma position as of Q1 2015 after selling out during the quarter.
Mason Street Advisors sold 1,020 Crescent Biopharma shares in Q1 2015, an estimated $734K.
Mason Street Advisors first reported a position in Crescent Biopharma in Q1 2014 and held it in 4 quarters.
Mason Street Advisors's Crescent Biopharma position peaked at $1.27M in Q1 2014.
28 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2015.

Based on Mason Street Advisors's 13F filing for Q1 2015, filed 15 May 2015.